Logo image of BTAI

BIOXCEL THERAPEUTICS INC (BTAI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BTAI - US09075P2048 - Common Stock

1.8813 USD
+0.01 (+0.6%)
Last: 12/16/2025, 12:46:57 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BTAI. BTAI was compared to 529 industry peers in the Biotechnology industry. BTAI may be in some trouble as it scores bad on both profitability and health. BTAI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BTAI has reported negative net income.
In the past year BTAI has reported a negative cash flow from operations.
In the past 5 years BTAI always reported negative net income.
BTAI had a negative operating cash flow in each of the past 5 years.
BTAI Yearly Net Income VS EBIT VS OCF VS FCFBTAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of BTAI (-152.28%) is worse than 86.39% of its industry peers.
Industry RankSector Rank
ROA -152.28%
ROE N/A
ROIC N/A
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTAI Yearly ROA, ROE, ROICBTAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

BTAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTAI Yearly Profit, Operating, Gross MarginsBTAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

1

2. Health

2.1 Basic Checks

BTAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BTAI has more shares outstanding
BTAI has more shares outstanding than it did 5 years ago.
BTAI has a worse debt/assets ratio than last year.
BTAI Yearly Shares OutstandingBTAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
BTAI Yearly Total Debt VS Total AssetsBTAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

BTAI has an Altman-Z score of -25.45. This is a bad value and indicates that BTAI is not financially healthy and even has some risk of bankruptcy.
BTAI has a worse Altman-Z score (-25.45) than 86.77% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -25.45
ROIC/WACCN/A
WACC8.95%
BTAI Yearly LT Debt VS Equity VS FCFBTAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

BTAI has a Current Ratio of 1.17. This is a normal value and indicates that BTAI is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.17, BTAI is not doing good in the industry: 86.58% of the companies in the same industry are doing better.
A Quick Ratio of 1.16 indicates that BTAI should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.16, BTAI is doing worse than 85.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 1.16
BTAI Yearly Current Assets VS Current LiabilitesBTAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

BTAI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.93%, which is quite impressive.
Looking at the last year, BTAI shows a very negative growth in Revenue. The Revenue has decreased by -66.96% in the last year.
EPS 1Y (TTM)71.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.42%
Revenue 1Y (TTM)-66.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.21%

3.2 Future

Based on estimates for the next years, BTAI will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.11% on average per year.
The Revenue is expected to grow by 151.92% on average over the next years. This is a very strong growth
EPS Next Y76.58%
EPS Next 2Y37.24%
EPS Next 3Y23.81%
EPS Next 5Y15.11%
Revenue Next Year-77.89%
Revenue Next 2Y6.85%
Revenue Next 3Y127.89%
Revenue Next 5Y151.92%

3.3 Evolution

BTAI Yearly Revenue VS EstimatesBTAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BTAI Yearly EPS VS EstimatesBTAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BTAI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BTAI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTAI Price Earnings VS Forward Price EarningsBTAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTAI Per share dataBTAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

BTAI's earnings are expected to grow with 23.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.24%
EPS Next 3Y23.81%

More info and screens

0

5. Dividend

5.1 Amount

BTAI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOXCEL THERAPEUTICS INC

NASDAQ:BTAI (12/16/2025, 12:46:57 PM)

1.8813

+0.01 (+0.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-25 2026-03-25/amc
Inst Owners12.08%
Inst Owner Change268.96%
Ins Owners2.05%
Ins Owner Change11.85%
Market Cap41.14M
Revenue(TTM)752.00K
Net Income(TTM)-68.21M
Analysts78.18
Price Target16.12 (756.85%)
Short Float %4.34%
Short Ratio1.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-55.46%
Min EPS beat(2)-81.51%
Max EPS beat(2)-29.42%
EPS beat(4)2
Avg EPS beat(4)3.13%
Min EPS beat(4)-81.51%
Max EPS beat(4)77.91%
EPS beat(8)5
Avg EPS beat(8)15.2%
EPS beat(12)5
Avg EPS beat(12)3.84%
EPS beat(16)7
Avg EPS beat(16)3.18%
Revenue beat(2)0
Avg Revenue beat(2)-53.86%
Min Revenue beat(2)-54.79%
Max Revenue beat(2)-52.94%
Revenue beat(4)0
Avg Revenue beat(4)-54.59%
Min Revenue beat(4)-61.4%
Max Revenue beat(4)-49.22%
Revenue beat(8)2
Avg Revenue beat(8)-35.61%
Revenue beat(12)2
Avg Revenue beat(12)-39.69%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.59%
PT rev (3m)-14.59%
EPS NQ rev (1m)-2%
EPS NQ rev (3m)-3.38%
EPS NY rev (1m)-8.55%
EPS NY rev (3m)-12.39%
Revenue NQ rev (1m)-20%
Revenue NQ rev (3m)-31.51%
Revenue NY rev (1m)-14.49%
Revenue NY rev (3m)-20.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 54.71
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.7
EYN/A
EPS(NY)-3.03
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.66
OCFYN/A
SpS0.03
BVpS-4.07
TBVpS-4.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -152.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-159.63%
ROA(5y)-112.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 1.16
Altman-Z -25.45
F-Score2
WACC8.95%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.42%
EPS Next Y76.58%
EPS Next 2Y37.24%
EPS Next 3Y23.81%
EPS Next 5Y15.11%
Revenue 1Y (TTM)-66.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-54.21%
Revenue Next Year-77.89%
Revenue Next 2Y6.85%
Revenue Next 3Y127.89%
Revenue Next 5Y151.92%
EBIT growth 1Y32.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.68%
EBIT Next 3Y0.54%
EBIT Next 5Y18.97%
FCF growth 1Y65.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.1%
OCF growth 3YN/A
OCF growth 5YN/A

BIOXCEL THERAPEUTICS INC / BTAI FAQ

Can you provide the ChartMill fundamental rating for BIOXCEL THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to BTAI.


What is the valuation status of BIOXCEL THERAPEUTICS INC (BTAI) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOXCEL THERAPEUTICS INC (BTAI). This can be considered as Overvalued.


What is the profitability of BTAI stock?

BIOXCEL THERAPEUTICS INC (BTAI) has a profitability rating of 0 / 10.


How financially healthy is BIOXCEL THERAPEUTICS INC?

The financial health rating of BIOXCEL THERAPEUTICS INC (BTAI) is 1 / 10.